Angiotensin III (human, mouse): Core RAAS Peptide for Cardiovascular and Neuroendocrine Research

Executive Summary: Angiotensin III (human, mouse) is a hexapeptide (Arg-Val-Tyr-Ile-His-Pro-Phe) generated via N-terminal cleavage of Angiotensin II by angiotensinase enzymes in erythrocytes and tissues (Oliveira et al., 2025). It accounts for approximately 40% of Angiotensin II's pressor activity and retains full capability to stimulate aldosterone secretion, acting primarily through the AT2 receptor but also engaging AT1 (APExBIO). The peptide exhibits high solubility (≥23.2 mg/mL in water) and molecular stability when desiccated at -20°C. Exogenous Angiotensin III reproduces key features of Angiotensin II in rodent neuroendocrine and cardiovascular models, making it valuable for RAAS pathway, hypertension, and SARS-CoV-2 viral pathogenesis research (Angiotensin III: Applied Workflows). These features position Angiotensin III as a versatile reagent for advanced experimental design in cardiovascular and neuroendocrine signaling studies.

Biological Rationale

Angiotensin III (CAS: 13602-53-4) is a naturally occurring renin-angiotensin-aldosterone system (RAAS) peptide. It is produced by the removal of the N-terminal Asp residue from Angiotensin II, primarily by aminopeptidase A activity in erythrocytes and tissues (Oliveira et al., 2025). The resulting hexapeptide maintains essential functional groups for receptor binding and downstream signaling. Angiotensin III is a critical mediator in blood pressure regulation, fluid balance, and neuroendocrine modulation. It serves as both a pressor activity mediator and aldosterone secretion inducer. In the central nervous system, Angiotensin III elicits dipsogenic (thirst-inducing) and pressor (blood pressure-increasing) responses in rodent models, confirming its functional overlap with Angiotensin II (Angiotensin III: A Versatile Cardiovascular Research Peptide).

Mechanism of Action of Angiotensin III (human, mouse)

The mechanism of Angiotensin III action involves high-affinity binding to both AT1 and AT2 angiotensin receptors, with a relative specificity for AT2. This interaction triggers canonical RAAS signaling pathways, such as G protein-coupled receptor activation, intracellular calcium mobilization, and modulation of aldosterone synthase expression. Angiotensin III retains full aldosterone-stimulating capability, paralleling Angiotensin II, but mediates only about 40% of the acute pressor response (APExBIO). In vivo, exogenous Angiotensin III suppresses renin release via negative feedback. In the context of viral pathogenesis, such as SARS-CoV-2, angiotensin peptides—including N-terminally truncated forms—modulate the binding affinity of the viral spike protein to cell-surface AXL, potentially influencing infection dynamics (Oliveira et al., 2025).

Evidence & Benchmarks

• Angiotensin III is generated in vivo from Angiotensin II by aminopeptidase A in erythrocytes and tissues (DOI:10.3390/ijms26136067).
• It mediates ~40% of Angiotensin II’s acute pressor activity and retains full aldosterone-stimulating effect (APExBIO).
• Angiotensin III binds both AT1 and AT2 receptors, with higher specificity for AT2 in some tissues (Angiotensin III: A Core RAAS Peptide).
• It is highly soluble: ≥23.2 mg/mL in water, ≥43.8 mg/mL in ethanol, and ≥93.1 mg/mL in DMSO at room temperature (APExBIO).
• In rodent brain models, exogenous Angiotensin III reliably induces pressor and dipsogenic responses (see Table 2 in DOI:10.3390/ijms26136067).
• Shorter N-terminal angiotensin peptides (including Angiotensin III) enhance SARS-CoV-2 spike binding to AXL (Figure 3, DOI:10.3390/ijms26136067).

Applications, Limits & Misconceptions

Angiotensin III (human, mouse) is used extensively in cardiovascular disease model development, neuroendocrine signaling studies, and viral pathogenesis research. It enables precise dissection of AT1 and AT2 receptor signaling, hypertension mechanisms, and aldosterone regulation. The peptide is also leveraged in SARS-CoV-2 research, where angiotensin fragments modulate viral entry via AXL. For advanced guidance, see Angiotensin III: Applied Workflows for Cardiovascular Research, which this article extends by detailing experimental parameters and recent viral findings.

Compared to Angiotensin III: A Versatile Cardiovascular Research Peptide, this review clarifies the molecular mechanism and updates benchmarks for viral pathogenesis models.

For an integrative perspective on experimental design and translational strategy, see Angiotensin III: Strategic Insights for Translational Research; the present article updates those insights by incorporating latest receptor signaling and solubility stability data.

Common Pitfalls or Misconceptions

• Angiotensin III is not a substitute for Angiotensin II in all cardiovascular models; it mediates only ~40% of the pressor response.
• The peptide does not demonstrate full efficacy in models requiring only AT1 receptor activation.
• Long-term storage in solution (even at -20°C) leads to decreased potency; always store lyophilized and desiccated.
• Angiotensin III does not enhance SARS-CoV-2 spike binding to ACE2 or NRP1 as robustly as it does to AXL (Oliveira et al., 2025).
• Not all commercially available Angiotensin III products are validated for both human and mouse sequence identity; verify source.

Workflow Integration & Parameters

Angiotensin III (A1043, APExBIO) is supplied as a solid with a molecular weight of 931.09 Da and formula C₄₆H₆₆N₁₂O₉. Recommended reconstitution is in sterile water, DMSO, or ethanol to ≥23.2, ≥93.1, or ≥43.8 mg/mL, respectively. For optimal biological activity, use freshly prepared solutions and store aliquots desiccated at -20°C. Do not freeze-thaw repeatedly. For cardiovascular and neuroendocrine studies, typical working concentrations range from 10 nM to 1 μM, depending on tissue and assay. In SARS-CoV-2 pathogenesis workflows, titrations should be benchmarked against Angiotensin II and IV controls as outlined in Oliveira et al., 2025.

Conclusion & Outlook

Angiotensin III (human, mouse) is a validated RAAS peptide for modeling aldosterone secretion, pressor activity, and neuroendocrine signaling. Its dual receptor specificity, high solubility, and stability profile make it a superior choice for precision cardiovascular and viral pathogenesis research. For further details or to procure the reagent, consult the official product page. Ongoing research continues to elucidate the broader implications of angiotensin peptides in infection biology and hypertension therapeutics.